Alcon and Amgen Sign Collaboration Agreement to Develop and Commercialize Innovative Therapies in Ophthalmology
Alcon, Inc. and Amgen announced a broad, multi-target collaboration to jointly research, develop, and commercialize therapeutics for the treatment of eye diseases. The agreement encompasses multiple biological targets and disease areas within the field of ophthalmology.
Under the terms of the agreement between Amgen and Alcon, Inc.'s affiliates, Alcon Research, Ltd. and Alcon Manufacturing, Ltd., the parties will jointly develop and commercialize candidates for ophthalmic therapies. Amgen will be responsible for providing existing and future molecules that have been or are identified to have potential utility in eye disease and will have the option to co-promote collaboration products. Alcon will lead clinical development and commercialization activities for molecules jointly selected by the companies. Amgen will grant Alcon an exclusive license within the field of ophthalmology for product candidates resulting from the collaboration but will retain rights for all non-ophthalmic uses.
At Amgen's election on a product-by-product basis, the parties will either share profits on commercial products or Alcon will pay Amgen performance milestones and royalties. No other financial terms were disclosed.
Other news from the department research and development
